Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose escalation study evaluating the safety, tolerability, and preliminary efficacy of ABOR2013 monotherapy or in combination with PD-1 monoclonal antibody in advanced non-small cell lung cancer with EGFR positive mutation

Next Previous
Trial Profile

Dose escalation study evaluating the safety, tolerability, and preliminary efficacy of ABOR2013 monotherapy or in combination with PD-1 monoclonal antibody in advanced non-small cell lung cancer with EGFR positive mutation

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABO-2013 (Primary) ; Sintilimab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man

Most Recent Events

  • 27 Jun 2025 New trial record
  • 30 Apr 2025 Result (n=30, at the data cut off October 29, 2024) presented at the 116th Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top